Krystal Biotech (KRYS) traded higher today as market attention snapped to a newly surfaced institutional ownership disclosure: an amended Schedule 13G/A showing The Vanguard Group reporting 0 shares and 0% beneficial ownership. The filing explicitly ties the change to an internal realignment that disaggregated certain Vanguard subsidiaries for SEC reporting, meaning the headline “0% stake” can reflect how ownership is reported rather than a clean read-through to net selling. (stocktitan.net)

Large-capitalization biotech names with concentrated institutional ownership can react sharply to changes in the ownership narrative, even when the underlying driver is technical. In this case, the amended filing emphasizes a reporting-structure shift and notes that other Vanguard-related entities may report holdings separately going forward, leaving room for investor uncertainty intraday—often enough to lift volatility and fuel momentum buying. (stocktitan.net)

Beyond the filing-driven chatter, investors continue to key on Krystal’s commercial trajectory and 2026 growth narrative tied to VYJUVEK and broader international expansion, with the company’s investor materials highlighting ongoing corporate messaging into March 2026. Recent company communications also flag scheduled investor visibility through conferences and presentations, which can help keep the stock bid on dips. (ir.krystalbio.com)